

Review of: "Comparative analysis between Polymerized Type I Collagen (Fibroquel) and Baricitinib as a potential treatment for moderate-severe COVID-19 in outpatients and inpatients"

Mohammad Saeed Kalantari Meybodi

Potential competing interests: No potential competing interests to declare.

Dear editor,

I read the manuscript entitled "Comparative analysis between Polymerized Type I Collagen (Fibroquel) and Baricitinib as a potential treatment for moderate-severe COVID-19 in outpatients and inpatients!" and I will mention some points:

1. Why was the Fibroquel chosen?
2. Is the prescription of Baricitinib a standard treatment for moderate-severe Covid-19?
3. The sample size is small.
4. The limitations of the study have not been mentioned.
5. More factors and parameters between the two groups should have been compared and analyzed.